DexCom, Inc.
DXCM
Classement en actions
#758
DexCom, Inc. is a medical technology company primarily focused on innovating,... DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
Prix de l'action
$85.72
Capitalisation boursière
$32.35B
Changement (1 jour)
-0.30%
Changement (1 an)
25.27%
Pays
US
Échange DexCom, Inc. (DXCM)
Catégorie
Healthcare
Bénéfices pour DexCom, Inc. (DXCM)
Bénéfices en Jun 2026 TTM : $1.28B
Selon les derniers rapports financiers de DexCom, Inc., les bénéfices actuels de l'entreprise sont de $1.28B. En 2024, l'entreprise a réalisé un bénéfice de $709.00M, une diminution par rapport à celui de 2023 qui était de $710.40M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour DexCom, Inc. de 2000 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $1.28B | 17.60% |
| 2025 | $1.09B | 53.51% |
| 2024 | $709.00M | -0.20% |
| 2023 | $710.40M | 81.78% |
| 2022 | $390.80M | 52.18% |
| 2021 | $256.80M | 14.13% |
| 2020 | $225.00M | 115.93% |
| 2019 | $104.20M | -182.37% |
| 2018 | $-126.50M | 160.29% |
| 2017 | $-48.60M | -25.12% |
| 2016 | $-64.90M | 12.87% |
| 2015 | $-57.50M | 157.85% |
| 2014 | $-22.30M | -25.17% |
| 2013 | $-29.80M | -46.59% |
| 2012 | $-55.80M | 24.70% |
| 2011 | $-44.75M | -18.89% |
| 2010 | $-55.17M | 3.08% |
| 2009 | $-53.52M | -3.01% |
| 2008 | $-55.18M | 20.28% |
| 2007 | $-45.88M | -1.55% |
| 2006 | $-46.60M | -99.85% |
| 2005 | $-30.89B | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $7.51B | 486.80% |
US
|
|
| $5.56B | 334.61% |
IE
|
|
| $5.15B | 302.19% |
US
|
|
| $3.86B | 201.64% |
US
|
|
| - | - |
DE
|
